Global Head of Rare and Neurologic Diseases Therapeutic Area
Dr. Pablo Sardi is the Global Head of Rare and Neurologic Diseases Therapeutic Area and a Scientific Fellow at Sanofi. In this capacity, Pablo leads several teams of scientists working with a variety of therapeutic modalities to discover and develop transformative medicines for patients with rare and neurologic diseases (including rare metabolic, lysosomal, renal, hematologic, skeletal, and muscular diseases; as well as neurologic diseases comprising multiple sclerosis, ALS/FTD, Parkinson’s disease, and others).
Dr. Sardi holds a PharmD, an M.S. in Biochemistry and a Ph.D. in Pharmacology from the University of Buenos Aires, Argentina. Pablo’s passion for helping patients led him to join industry to pursue novel and transformative therapeutic solutions. His research focused on unlocking the underlying mechanisms of genetic neurological diseases and developing the best therapeutic strategies to correct these faulty mechanisms. Dr. Sardi’s laboratory studied the roles of lysosomal dysfunction in metabolic and neurodegenerative diseases, including Parkinson’s diseases. Dr. Sardi and colleagues have made several original discoveries, including the validation of several therapeutic targets and biomarkers of disease. This work has enabled the clinical development of several therapies for lysosomal storage disorders and genetic forms of Parkinson’s disease. Dr. Sardi has authored 60+ publications in peer-reviewed journals and has served as reviewer for scientific journals, grant panel committees, and scientific advisory boards. Pablo is also member of several Neuroscience foundations and societies, a member of ISAB for Parkinson’s disease progression markers initiative and the co-chair of the steering committee for AMP-PD (Accelerating Medicines Partnership – Parkinson’s Disease).